Birkerød, Denmark

Christoph Rosenbohm

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 5.6

ph-index = 7

Forward Citations = 494(Granted Patents)


Location History:

  • Copenhagen, DK (2009 - 2013)
  • Birkerød, DK (2013)
  • Hoersholm, DK (2016)
  • Birkerod, DK (2012 - 2022)
  • Hørsholm, DK (2020 - 2023)

Company Filing History:


Years Active: 2009-2023

Loading Chart...
Loading Chart...
17 patents (USPTO):

Title: Christoph Rosenbohm: Innovator in Oligonucleotide Technology

Introduction

Christoph Rosenbohm is a distinguished inventor based in Birkerød, Denmark. He has made significant contributions to the field of oligonucleotide technology, holding a total of 17 patents. His work focuses on improving the efficiency and effectiveness of oligonucleotide synthesis and conjugation processes.

Latest Patents

One of his latest patents is the LNA-G process, which addresses challenges in de-protecting LNA oligonucleotides. This invention identifies a problem associated with the production of a +28 Da impurity when using DMF protected LNA G nucleosides. Rosenbohm's solution involves utilizing acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group. Another notable patent is related to the oligonucleotide conjugation process. This invention describes a method that employs a low-water content solvent environment, which enhances conjugation efficiency, reduces the amount of conjugate moiety required, and accelerates the reaction speed.

Career Highlights

Rosenbohm has worked with prominent companies in the biotechnology sector, including Roche Innovation Center Copenhagen A/S and Santaris Pharma A/S. His experience in these organizations has allowed him to refine his expertise in oligonucleotide research and development.

Collaborations

Throughout his career, Christoph has collaborated with notable professionals in the field, including Troels Koch and Signe M. Christensen. These partnerships have contributed to the advancement of his innovative projects and patents.

Conclusion

Christoph Rosenbohm is a key figure in the development of oligonucleotide technologies, with a strong portfolio of patents that address critical challenges in the field. His work continues to influence advancements in biotechnology and pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…